

**Ketoconazole and miconazole are antagonists of the human glucocorticoid  
receptor: Consequences on the expression and function of the constitutive  
androstane receptor and the pregnane X receptor \***

Cedric Duret, Martine Daujat-Chavanieu, Jean-Marc Pascussi, Lydiane Pichard-Garcia,  
Patrick Balaguer, Jean-Michel Fabre, Marie-José Vilarem, Patrick Maurel and Sabine Gerbal-  
Chaloin

Inserm, U632, Montpellier, F-34293 France ; Univ Montpellier 1, EA/3768, Montpellier, F-  
34000 France (C.D., M.D.-C., J.M.P., L.P.-G., J.M.F., M.J.V., P.M., S.G.-C.)

Inserm U439, Montpellier, F-34090 France (P.B.)

Service de Chirurgie Digestive, Hopital Saint Eloi, Montpellier, F-34295 (J.M.F.)

## Running title page

Running title: Ketoconazole and miconazole are hGR antagonists

Corresponding author: Sabine Gerbal-Chaloin, Inserm U632, Hepatic Physiopathology, 1919 route de Mende, 34293 Montpellier France; Tel: +33-4-6761 3361; Fax: +33-4-6752 3681; email: [gerbal@montp.inserm.fr](mailto:gerbal@montp.inserm.fr)

Number of text pages: 35

Number of tables: 0

Number of figures: 14

Number of references: 40

Abstract: 236 words

Introduction: 922 words

Discussion: 1497 words

Abbreviations: AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; CITCO, 6-(4-chlorophenyl)imidazo [2,1-*b*] [1,3] thiazole-5-carbaldehyde *O*-(3,4-dichlorobenzyl) oxime ; GAPDH, glyceraldehyde phosphate dehydrogenase; GR, glucocorticoid receptor; GST, glutathion S-transferase; MRP, multidrug resistance protein; PXR, pregnane X receptor; RXR, retinoid X receptor; SLC21A6, solute carrier family 21 form A6; UGT, UDP-glucuronosyl transferase; XMTS, xenobiotic metabolising and transporter systems.

## Abstract

The constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) play a major part in the control of drug metabolism and transport. We have previously shown that PXR and CAR expression is controlled by the glucocorticoid receptor (GR) and proposed the existence of a signal transmission cascade GR-(PXR/CAR)-drug metabolising and transporter systems. In the current study we investigated the effect of ketoconazole and other azole-derived drugs, miconazole and fluconazole on the transcriptional activity of the human GR in HeLa and HepG2 cells, and in primary human hepatocytes. The data show that ketoconazole inhibits GR transcriptional activity and competes with dexamethasone for hGR binding. In primary human hepatocytes ketoconazole inhibits the expression of: i) GR-responsive genes tyrosine aminotransferase and both PXR and CAR, ii) CAR and PXR target genes including cytochrome P450 (CYP) CYP2B6, CYP2C9, CYP3A4, UDP-glucuronosyltransferase (UGT1A1), glutathion-S-transferases (GSTA1 and A2) and transporter proteins (phase III) SLC21A6 and multidrug resistance protein (MRP2). In parallel experiments, ketoconazole affected neither the expression of GR, nor the expression of glyceraldehyde phosphate dehydrogenase, nor the inducible expression of CYP1A1 and 1A2. Miconazole behaved like ketoconazole, while fluconazole had no effect. We conclude that, in addition to their well known inhibitory effect on CYP enzyme activities, ketoconazole and miconazole are antagonists of hGR. These results provide a novel molecular mechanism by which these compounds may exert adverse and toxic effects on drug metabolism and other functions in man.

## Introduction

Several superfamilies of genes encoding xenobiotic metabolising and transporter systems (XMTS) play a critical role as the first line of defense of living organisms against the potential threat represented by foreign chemicals (Xu et al., 2005). XMTS include functionalisation enzymes (phase I) such as cytochromes P450 (CYP), conjugation enzymes (phase II) such as UDP-glucuronosyltransferases (UGT) and glutathion-S-transferases (GST) and transporter proteins (phase III) such as P-glycoprotein and multidrug resistance proteins (MRP). The coordinated mobilization of these systems in response to fluctuating levels of xenobiotics is mediated via three xenobiotic receptors (also called xenosensors): the aryl hydrocarbon receptor (AhR) (Whitlock, 1999), the pregnane X receptor (PXR) (Bertilsson et al., 1998; Lehmann et al., 1998) and the constitutive androstane receptor (CAR) (Sueyoshi et al., 1999). Upon activation by xenobiotics, these xenosensors bind to and transactivate cognate response elements present in the promoter of their target genes. This leads to an enhanced rate of XMTS gene transcription, and eventually to an increased rate of xenobiotic elimination.

Recent investigations from this laboratory have shown that the expression of PXR, CAR and RXR (retinoid X receptor, their common heterodimer partner) is under the control of the glucocorticoid receptor (GR) (Pascussi et al., 2003; Pascussi et al., 2000a; Pascussi et al., 2004; Pascussi et al., 2000b). In primary human hepatocytes, treatment of cells with submicromolar concentrations of dexamethasone enhanced PXR- and CAR-mediated induction of CYP3A4, CYP2B6 and CYP2C8 mRNAs, in response to various inducers including rifampicin and phenobarbital. This was accompanied by an increase in the expression of PXR, CAR and RXR mRNAs as well as of tyrosine aminotransferase (TAT) mRNA, a typical GR-responsive gene. In addition, the effect of dexamethasone was blocked by RU486, a typical GR antagonist. Further experiments revealed that GR was expressed

constitutively in primary human hepatocytes and that the effect of dexamethasone on PXR, CAR and RXR expression was not related to mRNA stabilisation. In subsequent investigations a functional glucocorticoid responsive element (GRE) was identified in the promoter of *CAR*. Thus, we proposed the existence of a cascade of signal transmission: GR-[PXR/CAR]-XMTS (Pascussi et al., 2004). This cascade explains the previously unresolved and long-standing issue of the enhancement of xenobiotic-mediated induction of CYP2B6, CYP2C8/9 and CYP3A4 mRNAs by prototypical activators of PXR and CAR in the presence of nanomolar concentrations of dexamethasone. However, and more importantly, this cascade implies that any process affecting the transcriptional activity of GR should subsequently affect the expression of PXR, CAR and RXR, and eventually the expression of XMTS, so that the ability of a cell or organism to metabolise and eliminate xenobiotics would be reduced.

Ketoconazole and other azole derivatives such as miconazole and fluconazole are antifungal drugs. These compounds inhibit the sterol 14- $\alpha$ -demethylase (*CYP51*) (Debeljak et al., 2003). This leads to the impairment of the synthesis of ergosterol from the cytoplasmic membrane, and eventually to the accumulation of 14- $\alpha$ -methylsterols which are highly toxic for the membrane-bound enzyme systems of fungi and thus for its growth (Vanden Bossche et al., 1995). Since the introduction of these drugs, numerous clinically significant drug-drug interactions have been reported with cyclosporin, tacrolimus, benzodiazepine hypnotics and anxiolytics, antidepressants and antipsychotics, and many others (Venkatakrishnan et al., 2000). The majority of these interactions are of metabolic origin and caused by the inhibition of various microsomal CYP enzymes notably CYP3A4, CYP2C9, CYP2C19, as well as other CYP genes and P-glycoprotein. Previous investigations have shown that ketoconazole is also a potent inhibitor of various mitochondrial CYP enzymes including CYP11A, CYP11B, involved in steroidogenesis, and CYP24 (Loose et al., 1983a). Basically, azole derivatives bind strongly to the CYP enzymes *via* direct ligation of a nitrogen atom of the azole ring to

the heme iron atom of the cytochrome (Jefcoate, 1978). Depending on the CYP enzyme and on the substrate, this interaction may lead to a more or less potent competitive or non-competitive inhibition of enzyme activity.

More than 20 years ago, Loose et al reported that ketoconazole is an antagonist of the GR in the rat (Loose et al., 1983b). They showed that ketoconazole competes with dexamethasone for binding to GR prepared from rat liver hepatoma cells, kidney and thymus. However, in contrast to the widely investigated inhibitory effect of this compound on CYP enzymes, this GR antagonist effect has not received much attention so far, and has not been tested in man. Yet, GR is involved in the regulation of numerous processes including developmental, metabolic, immunological and cognitive functions through its effects in target organs such as the liver, kidney, thymus, blood and in the Central Nervous System (Cole et al., 1995; Wintermantel et al., 2005). Because we have proposed the existence of the GR-[PXR/CAR]-XMTS cascade of signal transmission, we decided to examine the effect of ketoconazole and other azole compounds, first on the expression and transcriptional activity of GR, second on the mRNA expression of TAT, PXR, CAR and third on the mRNA expression of several XMTS including cytochromes P450 (CYP) CYP2B6, CYP2C9, CYP3A4, glutathion-S-transferases GSTA1, GSTA2, UDP-glucuronosyltransferase UGT1A1, SLC21A6, and multidrug resistance protein MRP2, in various cell lines and primary human hepatocytes. Our results show that ketoconazole and miconazole inhibit dexamethasone binding to and transcriptional activity of GR, repress the expression of PXR and CAR and eventually of their target genes involved in drug metabolism and transport. These results show that in addition to their well know inhibitory effect on CYP enzyme monooxygenase activities, azole derivatives are able to mediate a pleiotropic inhibitory effect on gene expression through their antagonist effect on hGR.

## **Materials and Methods**

**Materials.** Cell culture media and supplements were purchased from Invitrogen (Cergy Pontoise, France). Dexamethasone, ketoconazole, rifampicin, phenobarbital and mifepristone (RU486) were purchased from Sigma (St Quentin Fallavier, France). 2,3,7,8-tetrachlorodibenzo-*p*-dioxin from BCP Instruments (Lyon, France). 6-(4-chlorophenyl)imidazo [2,1-*b*] [1,3] thiazole-5-carbaldehyde *O*-(3,4-dichlorobenzyl) oxime (CITCO) was purchased from Biomol Research Labs Inc. (Plymouth, PA). Miconazole was obtained from Janssen Laboratory (Paris) and fluconazole from Pfizer (Paris). Collagen-coated culture dishes were purchased from BD Biosciences (Le Pont de Claix, France), FuGENE-6 transfection reagent from Roche (Mannheim, Germany),  $\alpha$ -<sup>32</sup>PdCTP,  $\alpha$ -<sup>32</sup>PdUTP, <sup>3</sup>H-dexamethasone and electrochemiluminescence-developing reagents from Amersham-Pharmacia Biotech (Amersham, United Kingdom).

**Liver samples and primary culture of human hepatocytes.** Human liver samples were obtained from seven patients: FT199, 42 year-old male, stenosis of the left hepatic channel (Caroli disease); FT212, 52 year-old male, metastasis of a colon tumor; FT245, 70 year-old female, adenocarcinoma; FT246, 50 year-old female who became an organ donor after a cerebral hemorrhage; FT257, 30 year-old female, hydatid cyst; FT259, 76 year-old male, hepatocellular carcinoma on non-cirrhotic liver; and FT261, 21 year-old female, adenoma. These tissues were removed for medical reasons unrelated to our research program. The tissue encompassing the tumor was dissected by the surgeon and sent for anatomopathologic studies, while the remaining tissue was used for hepatocyte preparation. No information on the patients was available to us, apart from age and sex and the reason for surgery. Importantly, pathological examination of the surgical specimen was in no way hindered by the procedure used to obtain primary hepatocytes; the tissues used for this study would otherwise have been immediately discarded. In all patients, viral serologic analysis (HBV,

HCV and HIV) was negative. Primary human hepatocytes were prepared and cultured as described elsewhere (Pichard-Garcia et al., 2002). The cells were plated into collagen-coated dishes at  $1.7 \times 10^5$  cells/cm<sup>2</sup> in a hormonally and chemically defined medium consisting of a mixture of William's E and Ham's F-12 (1:1 in volume). Forty-eight hours after plating, cells were cultured in the presence or absence of the indicated inducers for 24 hours.

**Cell culture and transfection.** HepG2 and HeLa cell lines were obtained from the European Collection of Cell Cultures (Salisbury, United Kingdom) and maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal calf serum, 1mM glutamine, 10mM sodium pyruvate and 100µg/ml penicillin and streptomycin. The stably transfected cell line HLMN was obtained by transfecting HeLa cells with the glucocorticoid responsive reporter gene MMTV-LUC-SVNeo as described (Balaguer et al., 1999; Dvorak et al., 2003). The pSG5-hGR, pSG5-hPXR, pBSEN-hCAR, pGL3(CYP3A4/XREM-7800-7200/-262/+11)-LUC, pTAT-(GRE)2-TK-LUC, and pGL3-CAR(-4711/+144)-LUC have previously been described (Gerbal-Chaloin et al., 2002; Pascussi et al., 2003; Pascussi et al., 2001). For reporter assays,  $6.10^5$  HepG2 or HeLa cells were transiently transfected with 10 ng of expression plasmid (pSG5-hGR, pSG5-hPXR) or 100 ng of pBSEN-hCAR together with 100 ng of luciferase reporter constructs pGL3-CAR(-4711/+144)-LUC or pGL3(CYP3A4/XREM-7800-7200/-262/+11)-LUC and 50 ng pSV-β-Galactosidase expression plasmid for transfection quality control. After 16 hours of serum-starvation, HepG2 cells transfected with pSG5-hGR and pGL3-CAR(-4711/+144)-LUC and stably transfected HMLN cell lines were treated with ketoconazole for one hour prior to dexamethasone treatment (0.1 µM) for 3 hours. After 24 hours, HepG2 cells transfected with pGL3(CYP3A4/XREM-7800-7200/-262/+11)-LUC and pSG5-hPXR or pBSEN-hCAR expression vectors were treated with



ketoconazole and rifampicine or ketoconazole alone, respectively for 24 hours and luciferase activity was measured.

**Total RNA Purification, Northern Blot and Ribonuclease Protection Assays.** Total RNA was isolated using TRIZOL reagent (Invitrogen). Twenty-five  $\mu\text{g}$  of total RNA were analyzed by northern-blot using  $\alpha$ - $^{32}\text{P}$ dCTP labeled rat glyceraldehyde-3-phosphate dehydrogenase cDNA probe for quality control or analyzed with human TAT or CYP1A1 complementary cDNA probes (Gerbal-Chaloin et al., 2006). For ribonuclease protection assays, 25 $\mu\text{g}$  of total RNA were analyzed using specific RNA probes directed against PXR and CAR as previously described (Gerbal-Chaloin et al., 2002).

**Quantitative Polymerase Chain Reaction.** cDNA was synthesised from 1 $\mu\text{g}$  of total RNA using M-MLV reverse transcriptase (Invitrogen) at 37°C for 50 min in the presence of random hexamers. One tenth was used for Q-PCR amplification using the Light Cycler apparatus (Roche Diagnostics Corporation, Meylan, France). The following program was used: an activation step at 95°C for 8 min was followed by 45 cycles of PCR (denaturation at 95°C for 15 seconds; annealing of 10 seconds at 65°C for CAR, PXR, CYP3A4, CYP2C9 and CYP2B6 or 70°C for the others ; elongation at 72°C for 10 seconds). Primers were as follows:

CYP3A4-S: 5'-CACAAACCGGAGGCCTTTTG-3'

CYP3A4-R: 5'-ATCCATGCTGTAGGCCCCAA-3'

CYP2C9-S: 5'- TCCTATCATTGACTTCCCG-3'

CYP2C9-R: 5'- AACTGCAGTGTTTTCCAAGC-3'

CYP2B6-S: 5'-CGCCTCCCACCAGGGCCCCGCC-3'

CYP2B6-R:5'-GGGGATATGGTGTGATCTTTGCCA-3'

PXR-S: 5'-TCCGGAAAGATCTGTGCTCT-3'

PXR-R: 5'-AGGGAGATCTGGTCCTCGAT-3'

CAR-S: 5'-CCGTGTGGGGTTCCAGGTAG-3'

CAR-R: 5'-CAGCCAGCAGGCCTAGCAAC-3'

TAT-S: 5'-AGGCCAGGTGGTCTGTGAGG-3'

TAT-R: 5'-AGGGGTGCCTCAGGACAGTG-3'

Actin-S: 5'-TGGGCATGGGTCAGAAGGAT-3'

Actin-R: 5'-TCCATCACGATGCCAGTGGT-3'

SLC21A6-S:5'-TCAATGGGAACCAGTCTGTGGA-3'

SLC21A6-R:5'-TGTGAGGTGCCTCCAAGTGC-3'

GSTA1-S: 5'-CTGCCCCGTATGTCCACCTGA-3'

GSTA1-R: 5'-GGGCTGCCAGGCTGTAGAAA-3'

GSTA2-S:5'-TTCGGTTGTCCAGCCACAAA-3'

GSTA2-R:5'-TGCACCAGCTTCATCCCATC-3'

UGT1A1-S:5'-GGTGA CTGTCCAGGACCTAT-3'

UGT1A1-R:5'-TAGTGGATTTTGGTGAAGGCAGTT-3'

MRP2-S:5'-GGCCCCAATGGCCTGTTGAA-3'

MRP2-R:5'-TGGAGGCTGCATCTTCGGGG-3'

GR-S : 5'-CCAACGGTGGCAATGTGAAA-3'

GR-R : 5'-CCGCCAGAGGAGAAAGCAAA-3'

The expression of  $\beta$ -actin was used for relative quantification. The calibration standard curves were generated using three 10-fold serial dilutions of the reverse-transcription samples prepared from human liver tissue. The measurements were performed in duplicate and all the primers were located in two different exons excepted for UGT1A1 (Assenat et al., 2004). Primers for CYP3A4, CYP2B6 and CYP2C9 have been designed specifically for these isoforms and do not recognize CYP3A5, CYP2B7 or CYP2C8/18/19, respectively. Moreover,

we verified after each run of RT-PCR that the melting curve of the amplified fragments monitored by the light cycler presented a single peak, as expected.

**Ligand binding assay.** Ligand binding assay was performed as described (Gerbal-Chaloin et al., 2006). Briefly, COS-1 cells were transfected with the pSG5-hGR expression plasmid. After 24 hours of culture in complete medium and 16 hours of serum starvation, cells were resuspended in binding buffer (5mM Tris-HCl, pH 7.4, 5% glycerol, 1mM EDTA, 10mM Na<sub>2</sub>MoO<sub>6</sub>(2H<sub>2</sub>O), 2mM β-mercaptoethanol), homogenized and centrifuged (1 hour, 35000 rpm at 4°C) and the supernatant was collected. The cytosol was then incubated with 3nM [<sup>3</sup>H]-dexamethasone alone or in combination with either unlabelled 3μM dexamethasone, 3μM RU486, ketoconazole, miconazole or fluconazole at the concentrations indicated in the text. After an overnight incubation at 4°C, bound and free steroid were separated by gel filtration using Sephadex LH-20 (Pharmacia, Guyancourt, France). Radioactivity was measured in a liquid scintillation counter (Canberra Packard, Savigny-le-Temple, France). Presence of GR in the cytosolic fraction was verified by western blot.

**Total protein extracts.** Hepatocytes (10<sup>7</sup>) were scrapped in cold PBS. After centrifugation the supernatant was removed. The pellet was resuspended in cold lysis buffer (150 mM sodium chloride, 50 mM Tris pH7.5, 0.1 mM sodium pyrophosphate, 1 mM EDTA, 0.2% Triton X-100, 1 mM DTT, 1 mM sodium vanadate) and sonicated. After centrifugation the supernatant was frozen at -80°C.

**Nuclear extracts.** Cells were washed in ice cold PBS and centrifuged 30 seconds at 10,000 g. The pellet was than resuspended in 50 μl of low salt buffer (20 mM HEPES pH 7.9, 10 mM potassium chloride, 0.1 mM sodium vanadate, 1 mM EDTA, 1 mM EGTA, 0.2% Nonidet P-

40, 10% glycerol, supplemented with a set of protease inhibitors). After 10 min of incubation on ice, the samples were centrifuged at 13,000 g for 2 min at 4°C, and the supernatants were taken as cytosolic extracts. Nuclei were resuspended in high salt buffer (20 mM HEPES pH 7.9, 420 mM sodium chloride, 10 mM potassium chloride, 0.1 mM sodium vanadate, 1 mM EDTA, 1 mM EGTA, 20% glycerol, supplemented with a set of protease inhibitors), and nuclear proteins were extracted by shaking on ice for 30 min. Samples were centrifuged at 13,000 g for 10 min at 4°C, and the supernatant were taken as nuclear extracts. Nuclear protein concentration was determined by bisinchoninic acid method.

***SDS-PAGE and Western blotting.*** Twenty five micrograms of protein samples were resolved by denaturing 8 % SDS-PAGE and transferred to nitrocellulose membrane (Millipore). Membranes were incubated with specific antibodies against hGR, hPXR or  $\beta$ -actin (SantaCruz, California).

***Statistical analysis.*** Statistical analysis of data obtained in *in vitro* experiments (ligand binding assay) and cell line transfection was carried out using the GraphPad software Inc., San Diego CA.

## Results

### *Ketoconazole is an antagonist of the human glucocorticoid receptor*

Hepatocytes from different liver donors (FT199, FT212, FT245, FT246) were maintained in a standard culture medium containing 0.1  $\mu$ M dexamethasone. Under these conditions, tyrosine aminotransferase (TAT) mRNA is expressed as previously reported (Pascussi et al., 2000a). However, when the cells were cultured for 24 hours in the presence of increasing concentrations of ketoconazole (KT, 10 and 20  $\mu$ M), the TAT mRNA levels evaluated by real time quantitative RT-PCR were reduced by 66 and 80%, respectively (**Figure 1A**). This inhibitory effect was confirmed by Northern-Blot analysis (**Figure 1B**). Control experiments revealed that under these conditions, ketoconazole was not toxic for the cells as assessed by the MTT test (not shown).

In order to understand the mechanism of this inhibition, and since TAT is a well known prototypical glucocorticoid receptor (hGR)-target gene we evaluated the effect of ketoconazole on the expression and transcriptional activity of this receptor. For this purpose, protein and RNA extracts from hepatocytes treated with increasing concentration of ketoconazole were analysed for GR expression by immunoblotting and RT-PCR. The results presented in **Figure 2** show that ketoconazole affected neither the accumulation of the protein nor of the mRNA. Next, we used HeLa cells (in which hGR is expressed constitutively) stably transfected with pMAMneo-luc plasmid in which the luciferase reporter gene is under the control of the glucocorticoid responsive element (GRE) of the mouse mammary tumor virus (HeLa-MMTV-luc) (Balaguer et al., 1999). Cells were cultured for 4 hours in the absence or presence of dexamethasone and in the presence of increasing concentrations of ketoconazole, and the luciferase activity measured. The results are shown in **Figure 3**. As expected, the reporter gene activity was very low in the absence of dexamethasone but was markedly enhanced (40-fold) when the glucocorticoid was present. Ketoconazole had no effect on

luciferase activity in the absence of dexamethasone. In the presence of dexamethasone, however, ketoconazole inhibited the reporter gene activity in a concentration-dependent manner with a  $IC_{50}$  of approximately  $30\mu M$ . Control experiments were carried out with RU486, a well known antagonist of hGR. RU486 behaved as a partial agonist when used alone, producing a 5-fold increase in the basal reporter activity, consistent with previous observations (Schulz et al., 2002). However, when added in the presence of dexamethasone, RU486 produced a strong inhibition (approximately 80%) of the reporter activity observed in the presence of dexamethasone alone. These observations suggest that, depending on the promoter and cellular contexts, binding of RU486 to hGR results in an equilibrium between hGR-corepressor and GR-coactivator which appears to be in favor of the GR-corepressor complex. The opposite situation prevails after binding of dexamethasone. These experiments suggest that ketoconazole inhibits the transcriptional activity of hGR.

Next, we determined whether ketoconazole affects the binding of dexamethasone to human GR *in vitro*. For this purpose, COS-1 cells were transfected with a pSG5-hGR expression vector. Cytosolic extracts were then incubated with radiolabeled [ $^3H$ ]-dexamethasone in the absence or presence of an excess (1000-fold) of unlabelled dexamethasone, RU486 or increasing concentrations of ketoconazole. After incubation overnight at  $4^{\circ}C$ , protein-bound and free dexamethasone were separated by gel filtration using Sephadex LH-20, and quantified. Control experiments were carried out with cytosolic extracts from untransfected COS-1 cells. The results are shown in **Figure 4**. As expected, the amount of protein-bound [ $^3H$ ]-dexamethasone was greatly reduced (>80%) by unlabeled dexamethasone and RU486, so that it reached the level observed in non-transfected COS-1 cell extracts. Ketoconazole reduced [ $^3H$ ]-dexamethasone binding to hGR in a concentration-dependent manner with a  $IC_{50}$  of approximately  $100\mu M$ . These results suggest that

ketoconazole interacts with hGR in such a way as to inhibit dexamethasone binding. In sum, the results presented in Figures 1-4 suggest that ketoconazole is an antagonist of hGR.

***Pleiotropic inhibitory effect of KT on the expression of CAR, PXR, CYP and other gene expression***

We have previously demonstrated that the expression of PXR and CAR genes is regulated, at least in part, by the GR in primary human hepatocytes (Pascussi et al., 2003; Pascussi et al., 2000a; Pascussi et al., 2000b). The finding that ketoconazole is an antagonist of hGR prompted us to evaluate the effect of this compound on the expression of these nuclear receptors. For this purpose, human hepatocytes (from four different cultures FT199, FT212, FT245, FT246) were incubated with 10 and 20  $\mu$ M ketoconazole for 24 hours and CAR and PXR mRNA levels were evaluated by RNase protection assay and real-time quantitative RT-PCR. The results are shown in **Figure 5A-B**. The levels of CAR and PXR mRNA were reduced by ketoconazole in a concentration-dependent manner, with 80 and 50% inhibition, respectively, for a concentration of 20  $\mu$ M. Next, protein extracts from the same cells were analyzed by immunoblotting using anti-PXR antibodies (no anti-human CAR antibody is currently available). The results presented in **Figure 5C** show that ketoconazole reduced the accumulation of PXR protein, in a concentration-dependent manner, with a 34% inhibition at 20  $\mu$ M, consistent with the effect on mRNA (**Figure 5B**).

We have previously identified and characterized a functional glucocorticoid responsive element (GRE) in the distal region of the CAR promoter (-4477/-4410) (Pascussi et al., 2003). We therefore decided to test the effect of ketoconazole on the activity of the CAR promoter. For this purpose, HepG2 cells were co-transfected with pGL3-CAR(-4711/+144)-LUC and pSG5-hGR expression vectors. After 16 hours of serum starvation, cells were cultured in the absence or presence of dexamethasone and in the absence or presence of

increasing concentrations of ketoconazole. The results are shown in **Figure 6**. Ketoconazole reduced the CAR-GRE transactivation in a concentration-dependent manner with an  $IC_{50}$  of approximately 25  $\mu$ M, that is, close to the  $IC_{50}$  value observed in HeLa cells with the MMTV-GRE construct (Figure 2). In control experiments, and as observed in Figure 3, RU486 alone behaved as a partial agonist producing a 60% increase in the basal reporter activity. However, when added in the presence of dexamethasone, RU486 produced a >50% inhibition of the reporter activity observed in the presence of dexamethasone alone.

In a next series of experiments, we evaluated the effect of ketoconazole on the transcriptional activity of PXR and CAR. For this purpose, HepG2 cells were transiently transfected with a hPXR or hCAR expression vector, in the presence of a reporter plasmid in which the luciferase gene is under the control of the PXR/CAR-responsive elements of CYP3A4. Then, cells were treated with increasing concentrations of ketoconazole and the luciferase activity was measured. The results are shown in **Figure 7**. Ketoconazole reduced both PXR and CAR transcriptional activity by approximately 35% at 20  $\mu$ M. In parallel experiments fluconazole had no effect. These results on PXR are consistent with those recently reported by Takeshita et al. (Takeshita et al., 2002) and suggest, in addition, that ketoconazole reduces hCAR transcriptional activity.

Expression of CYP3A4, CYP2B6 and CYP2C9 mRNAs is regulated by both CAR and PXR (Lehmann et al., 1998; Sueyoshi et al., 1999). The basal expression and induction of these messengers in response to rifampicin (a potent hPXR agonist), phenobarbital (a potent hCAR activator and PXR agonist) and CITCO (a specific CAR activator) (Maglich et al., 2003) were evaluated in the presence of ketoconazole. For this purpose, human hepatocytes (from different liver donors FT212, FT245, FT246, FT261) were cultured for 24 hours in the absence or presence of 20 $\mu$ M rifampicin, 500  $\mu$ M phenobarbital, or 100 nM CITCO, and in the absence or presence of increasing concentrations of ketoconazole. Note that in cultured



human hepatocytes, CITCO is a specific CAR activator for concentrations up to 100 nM; at greater concentrations this compounds activates PXR as well. Total RNA was then extracted and analyzed by Northern blot and real-time RT-PCR. The results are shown in Figure **8A-C and 9A-B**. In the absence of ketoconazole, CYP3A4, CYP2B6 and CYP2C9 mRNA expression was enhanced as expected in the presence of rifampicin, phenobarbital or CITCO. However in all cases, the presence of ketoconazole reduced the levels of these messengers. The presence of a functional GRE element in the promoter of CYP2C9 has previously been reported (Gerbai-Chaloin et al., 2002). This is consistent with the observation that the basal expression of this gene is maintained at a substantial level in primary human hepatocyte cultures, even in the absence of CAR or PXR activators (Pichard-Garcia et al., 2002). Interestingly, the CYP2C9 mRNA basal level was reduced by 50% in cells exposed to 20 $\mu$ M ketoconazole (**Figure 8C**). In control experiments carried out in parallel in the same cultures, ketoconazole did not affect the expression of CYP1A1 and 1A2 mRNA in cells exposed to dioxin, nor did it affect the level of GAPDH mRNA (**Figure 8D**).

In a next series of experiments we evaluated the effect of ketoconazole on the mRNA expression of phase II and phase III systems including UGT1A1, GSTA1, GSTA2, SLC21A6, and MRP2. Previous studies in animals or in hepatoma cell lines have shown that the inducible expression of all these genes is controlled by CAR and/or PXR (Huang et al., 2003; Kast et al., 2002; Sugatani et al., 2005). Human hepatocytes (from two different liver donors FT245, FT246) were cultured for 24 hours in the absence or presence of rifampicin and phenobarbital, and in the absence or presence of increasing concentrations of ketoconazole. Total RNA was then extracted and analyzed by real-time RT-PCR. The results are shown in **Figure 10**. In the absence of ketoconazole, the expression of these genes was either slightly enhanced (GST1A1, although to a much lower extent than that observed with CYP2 and CYP3 genes) or not significantly affected (others) by rifampicin and phenobarbital. This may

result from the fact that a limited number of human hepatocyte cultures have been analyzed and that the fold-induction of phase II and III genes is in general much smaller than that observed with CYP genes. However, in all cases, the presence of ketoconazole reduced the levels of the messengers in a concentration dependent manner (>50% at 20  $\mu$ M). Interestingly, ketoconazole also reduced the basal expression of all these genes in uninduced cells, as observed with CYP2C9 (Figure 8C), except for MRP2 which was not significantly affected. This suggests that GR plays a role in the basal expression of these genes. Indeed, this was shown to be the case for UGT1A1 (Sugatani et al., 2005), while in contrast, the MRP2 promoter was shown not to be regulated by glucocorticoids (Pulaski et al., 2005). Whether or not the basal expression of GSTA1, GSTA2, and SLC21A6 is under the control of GR is presently unknown. However, in recent work using these human hepatocyte cultures, we observed that the basal expression of all these genes (and interestingly again, except MRP2) was also down-regulated in response to  $\text{IL-1}\beta$  through NF $\kappa$ B-mediated inhibition of GR transcriptional activity (Assenat et al., 2004). In sum, the data presented in Figures 5-10 show that ketoconazole is a potent inhibitor of the expression and transcriptional activity of nuclear receptors CAR and PXR, and of the xenobiotic-inducible expression of CAR and PXR target genes. The major part of this effect most likely results from the fact that ketoconazole is an antagonist of GR which controls, at least in part, CAR and PXR expression.

### ***Effect of other azole derivatives on GR activity and target gene expression***

In addition to ketoconazole, other azole derivatives are currently in use. It seems therefore of interest to evaluate their effect on the transcriptional activity of the human GR. Miconazole and fluconazole were investigated in this respect. In a first series of experiments, we evaluated the effect of azole derivatives on the transcriptional activity of hGR, using the

HeLa cell system described above (Figure 3). Cells were cultured for 4 hours in the absence or presence of dexamethasone and in the presence of increasing concentrations of ketoconazole or other azole compounds, and the luciferase activity was measured. The results are shown in **Figure 11**. The compounds tested had no effect on the luciferase activity in the absence of dexamethasone. In the presence of dexamethasone, however, miconazole markedly inhibited the reporter gene activity with a  $IC_{50}$  of  $<10 \mu\text{M}$ , while fluconazole had no effect.

Next we tested whether these azole derivatives affect the binding of dexamethasone to hGR. Cytosolic extracts from COS-1 cells transfected with a pSG5-hGR expression vector were incubated with radiolabeled [ $^3\text{H}$ ]-dexamethasone in the absence or presence of an excess (1000-fold) of unlabelled dexamethasone, or of increasing concentrations of the compounds tested, or of ketoconazole used as a control. Dexamethasone binding was analyzed as reported above (Figure 4). The results are shown in **Figure 12**. As observed with ketoconazole, miconazole strongly reduced [ $^3\text{H}$ ]-dexamethasone binding to hGR in a concentration-dependent manner with a  $IC_{50}$  of approximately  $10 \mu\text{M}$ . These results suggest that miconazole interacts with hGR in such a way as to inhibit dexamethasone binding. In contrast, fluconazole had no effect.

In order to further confirm these observations, we investigated the effect of these compounds on the expression of TAT, CAR and PXR mRNA in human hepatocytes prepared from two different donors (FT257, FT259). The experimental conditions were the same as those described above, and ketoconazole was used as a control. The results are reported in **Figure 13**. In agreement with the data presented in Figures 11 and 12, miconazole was a potent inhibitor of TAT, CAR and PXR mRNA expression, while fluconazole had no effect. In sum, these results (Figures 11-13) suggest that miconazole, like ketoconazole, is an hGR antagonist, while fluconazole is not.

It is interesting that fluconazole does not apparently affect hGR activity in contrast to ketoconazole and miconazole. To further confirm this point, we evaluated the effect of this compound on the inducible expression of CYP3A4 and CYP2B6 by rifampicin and phenobarbital in primary human hepatocytes. The results shown in **Figure 14** clearly confirm that fluconazole does not affect the expression of PXR/CAR target genes.

## Discussion

Since the introduction of antifungal azole-derived drugs in the beginning of the 1980s, an impressive number of studies has been devoted to their adverse effects and toxicity, including notably serious and sometimes fatal drug-drug interactions, due to their inhibitory effects on the activity of CYP enzyme (Venkatakrisnan et al., 2000). The results reported here provide a novel molecular mechanism by which these compounds affect drug metabolism and other functions in man. We show that ketoconazole and miconazole are antagonists of the human GR, but do not affect the receptor protein expression. Since this receptor appears to be involved in the control of a number of cellular processes (Cole et al., 1995; Wintermantel et al., 2005), this effect is worrying and likely to result in adverse and toxic effects. As shown in detail here, the down-regulation of many genes involved in the control of detoxication appears to be one of the consequences of this antagonist effect.

Previous investigations from this laboratory have revealed the existence of the signal transmission cascade GR-[PXR/CAR]-XMTS (Pascussi et al., 2003; Pascussi et al., 2000a; Pascussi et al., 2004; Pascussi et al., 2000b). This implies that GR indirectly controls the inducible expression of XMTS including members of the CYP2B and CYP3A subfamilies, by up-regulating the expression of PXR and CAR. Under normal physiological conditions, the impact of this cascade is expected to be unremarked. However, under circumstances where the transcriptional activity of GR becomes limiting, the importance of the cascade may be revealed. This is the case when primary human hepatocytes are treated with ketoconazole and miconazole. As a consequence of their antagonist effect on hGR, these compounds directly decrease the expression of genes known to be controlled in part by GR such as TAT, CAR, PXR, CYP2C9, UGT1A1, and/or indirectly decrease the expression of genes known to be regulated by CAR and PXR, including CYP2B6, CYP2C9, CYP3A4, UGT1A1, GSTA1, GSTA2, and SLC21A6. Note that the inducibility of some of these phase II and phase III

genes has only been tested in animals or in human hepatoma cell lines. This repression is specific first because neither GR, nor GAPDH, nor actin, nor the TCDD-inducible expression of CYP1A1 and CYP1A2 mRNAs were affected in the same cells, and second because fluconazole, a structurally related compound, had no effect. These azole derivatives appear therefore not only to be potent inhibitors of CYP enzymes, but also to be repressors of CYP (and other XMTS) expression *via* inhibition of the GR transcriptional activity, through the GR-[CAR-PXR]-XMTS cascade. Interestingly, several methylsulfonyl-PCBs have been recently shown to behave as GR antagonists in a rat hepatoma cell line (Johansson et al., 2005).

Other situations leading to the modification of XMTS gene expression, through the inhibition of GR transcriptional activity, have been revealed in two recent studies (Assenat et al., 2004; Dvorak et al., 2003). In the first study, Dvorak et al. showed that the inhibitory effect of colchicine (a tubulin network disruptor) on *CYP2* and *CYP3* gene expression is mediated *via* alteration of the cytoskeleton, the integrity of which appears to be critical for GR nuclear translocation. In the second study, Assenat et al. showed that the pleiotropic repressive effect of interleukin-1 $\beta$  on XMTS is mediated *via* the activation of NF $\kappa$ B, a transcription factor known to interact with and block the transcriptional activity of GR. In both cases, the stimulus by colchicine and Il-1 $\beta$ , respectively, did repress the expression of TAT, CAR and PXR and subsequently of several CAR- and PXR-dependent XMTS.

The transcriptional activity of nuclear receptors is modulated *via* ligand-dependent interactions with coactivators and corepressors which possess and/or recruit histone acetyltransferases and histone deacetylases, respectively (Mangelsdorf et al., 1995; Wang et al., 2004). The relative balance of receptor interaction with coactivators and corepressors therefore determines the specific promoter activity. Recently, Takeshita and co-workers reported on the effect of ketoconazole on the transcriptional activity of PXR in HepG2 cells

(Takeshita et al., 2002). Using co-transfection experiments and a mammalian two-hybrid assay, these authors showed that ketoconazole: i) partially inhibits the corticosterone-dependent transcriptional activity of PXR whereas the drug shows only a weak agonist activity in the absence of the steroid, and ii) strongly reduces the interaction between PXR and SRC-1 (steroid receptor coactivator-1), as well as between PXR and SMRT (silencing mediator of thyroid receptor). The authors concluded that ketoconazole acts as an antagonist of PXR when the receptor is activated by a ligand, although they did not identify the molecular mechanism by which ketoconazole interacts with the receptor complex. In the current study, we confirmed the partial inhibitory effect (35% at 20  $\mu$ M) of ketoconazole on the transcriptional activity of PXR and, in addition, we observed a similar inhibitory effect on CAR. This last observation is reminiscent of the fact that clotrimazole, another azole derivative, is a well known hCAR antagonist (Maglich et al., 2003; Moore et al., 2000). However, clotrimazole is a PXR agonist. It appears therefore that imidazole derivatives are able to affect differently the transcriptional activity of nuclear receptors. The inhibitory effect of ketoconazole on the transcriptional activity of PXR and CAR cannot explain all the observations presented in this report, notably on TAT, CAR and PXR mRNA repression. However, it may contribute to the reduction of CYP and other XMTS mRNA expression observed in human hepatocytes. Indeed, the antagonist effect of ketoconazole on both GR and PXR/CAR should be additive.

The plasma concentrations of the azole-derived drugs investigated here and used in the treatment of fungus infections ranges from 2 to 10  $\mu$ M after therapeutic dosing (Venkatakrisnan et al., 2000). These concentrations are in the same range as those used in the present work. In addition, ketoconazole is used in the treatment of prostate cancers at high doses (up to 400 mg 3 times a day), and circulating levels are likely to be even greater in these patients (Oh, 2002). This suggests that inhibition of the expression of GR target genes *in vivo*

is a likely possibility. Yet, the clinical consequences on drug metabolism of the antagonist effect of ketoconazole and miconazole on GR are difficult to evaluate, because drug metabolism activity is generally assessed in patients by measuring pharmacokinetic parameters characterising the parent drug and/or its metabolite(s). In this condition, the GR antagonist effect is expected to reinforce the pure enzyme inhibitory effect, both effects eventually leading to a reduction in the rate of drug metabolism. It is therefore likely that the strong inhibitory effect of azole derivatives on CYP enzyme activities has almost totally overshadowed their repressor effect on CYP and other XMTS gene expression via antagonism of GR. Interestingly, however, some reports in the literature reveal possible clinical consequences of the antagonist effect of ketoconazole on GR in some pathological situations. The hypothalamo-pituitary adrenal (HPA) axis controls a number of neuronal and endocrine functions (McQuade and Young, 2000). Cortisol, the final product of the HPA axis mediates a number of central and peripheral effects *via* the GR. HPA dysfunction leading to hypercortisolaemia is responsible for disorders such as depression and drug addiction. In patients with depression, basal plasma cortisol levels are higher than in healthy control subjects, and during episodes of remission, cortisol concentrations are lower than in illness periods. Selective inactivation of GR in the brains of mice by cre/lox strategy profoundly reduced self-administration of cocaine and suppressed sensitization, two experimental procedures considered to be relevant models for addiction (Deroche-Gamonet et al., 2003; Wintermantel et al., 2005). It has accordingly been proposed that hypercortisolaemia is, in some way, responsible for the pathogenesis of the clinical symptoms. Thus, among the arsenal of approaches designed to treat mood disorders or drug addiction, various strategies rely on the use of antigluocorticoids. In this respect, Deroche-Gamonet et al., demonstrated that RU486 reduced in a dose-dependent manner the motivation of mice to self-administer cocaine. Interestingly, two previous investigations suggest that ketoconazole might help in



treating these disorders. In adult male Wistar rats which are allowed alternating periods of cocaine self-administration, treatment with ketoconazole significantly reduced low dose cocaine self-administration, whereas the compound had no effect on corticosterone levels in rats not submitted to cocaine treatment (Goeders et al., 1998). In another study, ketoconazole compared to placebo improved the symptoms of depression in hypercortisolaemic patients, without affecting the plasma cortisol levels (Wolkowitz et al., 1999). In both studies, ketoconazole by itself did not affect cortisol blood levels. It is therefore possible that the beneficial therapeutic effect of ketoconazole observed in these two studies resulted from the reduction of the detrimental effects of high cortisol/corticosterone blood levels because of the antagonist effect of the drug on GR.

In conclusion, ketoconazole and miconazole are not only potent inhibitors of a number of CYP enzymes, but also antagonists of hGR, a receptor involved in the control of large batteries of genes. Since these drugs are currently used worldwide in the treatment of fungal infections and cancer, the biological consequences of their interaction with the hGR need to be investigated in more detail.

## References

- Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ and Pascussi JM (2004) Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. *Hepatology* **40**(4):951-960.
- Balaguer P, Francois F, Comunale F, Fenet H, Boussioux AM, Pons M, Nicolas JC and Casellas C (1999) Reporter cell lines to study the estrogenic effects of xenoestrogens. *Sci Total Environ* **233**(1-3):47-56.
- Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeborg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *Proc Natl Acad Sci U S A* **95**(21):12208-12213.
- Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K and Schutz G (1995) Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. *Genes Dev* **9**(13):1608-1621.
- Debeljak N, Fink M and Rozman D (2003) Many facets of mammalian lanosterol 14alpha-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. *Arch Biochem Biophys* **409**(1):159-171.
- Deroche-Gamonet V, Sillaber I, Aouizerate B, Izawa R, Jaber M, Ghozland S, Kellendonk C, Le Moal M, Spanagel R, Schutz G, Tronche F and Piazza PV (2003) The glucocorticoid receptor as a potential target to reduce cocaine abuse. *J Neurosci* **23**(11):4785-4790.
- Dvorak Z, Modriansky M, Pichard-Garcia L, Balaguer P, Vilarem MJ, Ulrichova J, Maurel P and Pascussi JM (2003) Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. *Mol Pharmacol* **64**(1):160-169.
- Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ and Maurel P (2002) Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. *J Biol Chem* **277**(1):209-217.
- Gerbal-Chaloin S, Pichard-Garcia L, Fabre JM, Sa-Cunha A, Poellinger L, Maurel P and Daujat-Chavanieu M (2006) Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. *Cell Signal* **18**(5):740-750.
- Goeders NE, Peltier RL and Guerin GF (1998) Ketoconazole reduces low dose cocaine self-administration in rats. *Drug Alcohol Depend* **53**(1):67-77.
- Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R and Moore DD (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). *Proc Natl Acad Sci U S A* **100**(7):4156-4161.
- Jefcoate CR (1978) Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. *Methods Enzymol* **52**:258-279.
- Johansson M, Johansson N and Lund BO (2005) Xenobiotics and the glucocorticoid receptor: additive antagonistic effects on tyrosine aminotransferase activity in rat hepatoma cells. *Basic Clin Pharmacol Toxicol* **96**(4):309-315.
- Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM and Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. *J Biol Chem* **277**(4):2908-2915.

- Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J Clin Invest* **102**(5):1016-1023.
- Loose DS, Kan PB, Hirst MA, Marcus RA and Feldman D (1983a) Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. *J Clin Invest* **71**(5):1495-1499.
- Loose DS, Stover EP and Feldman D (1983b) Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. *J Clin Invest* **72**(1):404-408.
- Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM and Moore JT (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J Biol Chem* **278**(19):17277-17283.
- Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM (1995) The nuclear receptor superfamily: the second decade. *Cell* **83**(6):835-839.
- McQuade R and Young AH (2000) Future therapeutic targets in mood disorders: the glucocorticoid receptor. *Br J Psychiatry* **177**:390-395.
- Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL and Kliewer SA (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. *J Biol Chem* **275**(20):15122-15127.
- Oh WK (2002) Secondary hormonal therapies in the treatment of prostate cancer. *Urology* **60**(3 Suppl 1):87-92; discussion 93.
- Pascussi J, Busson-Le Coniat M, Maurel P and Vilarem M (2003) Transcriptional Analysis of the Orphan Nuclear Receptor Constitutive Androstane Receptor (NR1I3) Gene Promoter: Identification of a Distal Glucocorticoid Response Element. *Mol Endocrinol* **17**(1):42-55.
- Pascussi JM, Drocourt L, Fabre JM, Maurel P and Vilarem MJ (2000a) Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. *Mol Pharmacol* **58**(2):361-372.
- Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P and Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. *Eur J Biochem* **268**(24):6346-6358.
- Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ and Maurel P (2004) Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. *Xenobiotica* **34**(7):633-664.
- Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P and Vilarem MJ (2000b) Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. *Mol Pharmacol* **58**(6):1441-1450.
- Pichard-Garcia L, Gerbal-Chaloin S, Ferrini JB, Fabre JM and Maurel P (2002) Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression. *Methods Enzymol* **357**:311-321.
- Pulaski L, Kania K, Ratajewski M, Uchiumi T, Kuwano M and Bartosz G (2005) Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. *J Steroid Biochem Mol Biol* **96**(3-4):229-234.

- Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzl T and Renkawitz R (2002) RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. *J Biol Chem* **277**(29):26238-26243.
- Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. *J Biol Chem* **274**(10):6043-6046.
- Sugatani J, Nishitani S, Yamakawa K, Yoshinari K, Sueyoshi T, Negishi M and Miwa M (2005) Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. *Mol Pharmacol* **67**(3):845-855.
- Takeshita A, Taguchi M, Koibuchi N and Ozawa Y (2002) Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. *J Biol Chem* **277**(36):32453-32458.
- Vanden Bossche H, Koymans L and Moereels H (1995) P450 inhibitors of use in medical treatment: focus on mechanisms of action. *Pharmacol Ther* **67**(1):79-100.
- Venkatakrishnan K, von Moltke LL and Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. *Clin Pharmacokinet* **38**(2):111-180.
- Wang Q, Blackford JA, Jr., Song LN, Huang Y, Cho S and Simons SS, Jr. (2004) Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors. *Mol Endocrinol* **18**(6):1376-1395.
- Whitlock JP, Jr. (1999) Induction of cytochrome P4501A1. *Annu Rev Pharmacol Toxicol* **39**:103-125.
- Wintermantel TM, Berger S, Greiner EF and Schutz G (2005) Evaluation of steroid receptor function by gene targeting in mice. *J Steroid Biochem Mol Biol* **93**(2-5):107-112.
- Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R and Canick J (1999) Antigluocorticoid treatment of depression: double-blind ketoconazole. *Biol Psychiatry* **45**(8):1070-1074.
- Xu C, Li CY and Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. *Arch Pharm Res* **28**(3):249-268.

### **Footnotes**

\* This work was supported in part by the European Economic Community (STREP Predictomics, contract LSHB-CT-2004-504761). CD was supported by a fellowship Inserm-Région Languedoc Roussillon.

Reprint requests: Sabine Gerbal-Chaloin, Inserm U632, 1919 Route de Mende, 34293

Montpellier France. Email: [gerbal@montp.inserm.fr](mailto:gerbal@montp.inserm.fr)

## Figure legends

### **Figure 1. Ketoconazole reduces TAT mRNA expression in cultured human hepatocytes**

Primary human hepatocytes were cultured for 24 hours in the absence or presence of 10 or 20 $\mu$ M ketoconazole (KT10 and KT20). (A) TAT mRNA level was analyzed by quantitative real-time PCR and  $\beta$ -actin was used to normalize the data. Mean results from three cultures (FT212, 245 and 246) are expressed as a percentage of controls. (B) TAT mRNA level was analyzed by northern-blot. GAPDH mRNA was used as a control (culture FT199).

### **Figure 2. Ketoconazole does not affect GR expression in cultured human hepatocytes**

Primary human hepatocytes were cultured for 24 hours in the absence or presence of 10 or 20 $\mu$ M ketoconazole (KT10 and KT20). (A) GR protein level was analyzed by immunoblotting of total protein extracts and  $\beta$ -actin protein was used as a loading control. Results obtained with culture FT199 and representative of culture FT212. (B) GR mRNA level was analyzed by real-time quantitative RT-PCR.  $\beta$ -Actin mRNA was used as a control. Mean results from cultures FT212, 245, 246.

### **Figure 3. Ketoconazole inhibits GRE-luc transactivation in HeLa cells**

HeLa-MMTV-luc cells were cultured for 4 hours in the absence (DMSO, vehicle) or presence of 100 nM dexamethasone (DEX) and increasing concentrations of ketoconazole (KT10-KT40) or 1 $\mu$ M RU486 (RU1). Cell lysates were prepared and analyzed for luciferase activity and protein content. Data are normalized with respect to those obtained in DMSO-treated cells. Error bars represent the standard deviations of five independent experiments. Statistical analysis, Student t test: \*  $p < 0.05$

### **Figure 4. Ketoconazole displaces dexamethasone from hGR *in vitro***

Cytosolic extracts were prepared from pSG-5-hGR transiently transfected COS-1 cells, and incubated with 3nM [<sup>3</sup>H]-dexamethasone alone (100% binding) or in combination with either unlabelled 3μM dexamethasone, 3μM RU486 or increasing concentrations of ketoconazole (KT). Nontransfected COS-1 cells (NT) were used as a negative control. Bound and free dexamethasone were separated by gel filtration using a Sephadex LH-20 column. Error bars represent the standard deviations of 3 independent experiments. Statistical analysis, Student t test: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

**Figure 5. Ketoconazole reduces PXR and CAR mRNA levels and PXR protein level in cultured human hepatocytes**

Primary human hepatocytes were incubated with 10 and 20μM ketoconazole (KT10, KT20) for 24 hours. Total RNA was extracted and analyzed by real-time quantitative RT-PCR for the evaluation of CAR (A) and PXR (B) mRNA levels. Mean results from three cultures (FT212, 245 and 246) were normalized with respect to β-actin mRNA levels and are expressed as a percentage of control (untreated cells, UT). CAR and PXR mRNA accumulation was also evaluated by RNase Protection Assay using specific RNA probes (results presented from FT199). (C) Nuclear protein extracts from the same cells were analyzed by immunoblotting using anti-PXR antibodies (results presented from culture FT261). Upper panel: proteins labeled with Commassie Blue. Lower panel: immunoblot analysis of PXR. Huh7-hPXR: Huh-7 cells transfected with pSG5-hPXR expression vector. MW: molecular weight markers. The relative levels of PXR protein are given below the blot.

**Figure 6. Ketoconazole inhibits CAR-promoter transactivation in HepG2 cells**

HepG2 cells were transiently co-transfected for 16 hours with plasmids harboring a reporter gene construct pGL3-CAR(-4711/+144)-LUC, an hGR expression vector (pSG-5-hGR), and a

transfection marker (pSV- $\beta$ -galactosidase). After washing, cells were cultured for 4 hours in the absence (DMSO, vehicle) or presence of 100nM dexamethasone (DEX) and increasing concentrations (10 to 40 $\mu$ M) of ketoconazole (KT). Cell lysates were prepared and analyzed for both luciferase and  $\beta$ -galactosidase activities. Results are normalized with respect to untreated cells (DMSO) as control. Error bars represent the standard deviations of four independent experiments. Statistical analysis, Student t test: \*  $p < 0.05$ , \*\*\*  $p < 0.001$ .

**Figure 7. Ketoconazole inhibits CYP3A4-promoter transactivation in HepG2 cells**

A. HepG2 cells were transiently co-transfected for 16 hours with plasmids harboring a reporter gene construct pGL3(CYP3A4/XREM-7800-7200/-262/+11)-LUC, a hPXR expression vector (pSG5-hPXR), and a transfection marker (pSV- $\beta$ -galactosidase). After washing, cells were cultured for 24 hours in the absence (DMSO, vehicle) or presence of 10  $\mu$ M rifampicin (RIF) and increasing concentrations (2 to 20  $\mu$ M) of ketoconazole (KT) or fluconazole (F). Cell lysates were prepared and analyzed for both luciferase and  $\beta$ -galactosidase activities. Results are normalized with respect to untreated cells (no RIF) as control. Error bars represent the standard deviations of four independent experiments.

B. HepG2 cells were transiently co-transfected for 16 hours with plasmids harboring a reporter gene construct pGL3(CYP3A4/XREM-7800-7200/-262/+11)-LUC, a transfection marker (pSV- $\beta$ -galactosidase), and with (+CAR) or without (-CAR) a hCAR expression vector pBSEN-hCAR. After washing, cells were cultured for 24 hours in the absence or presence of increasing concentrations (2 to 20  $\mu$ M) of ketoconazole (KT) or fluconazole (F). Cell lysates were prepared and analyzed for both luciferase and  $\beta$ -galactosidase activities. Results are normalized with respect to cells that were not transfected with pBSEN-hCAR as control. Error bars represent the standard deviations of four independent experiments. Statistical analysis, Student t test: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .



**Figure 8. Ketoconazole reduces the inducible expression of CYP3A4, CYP2B6 and CYP2C9 mRNA in cultured human hepatocytes treated with rifampicin and phenobarbital**

Primary human hepatocytes were cultured for 24 hours in the absence (DMSO) or presence of 20 $\mu$ M rifampicin (RIF) or 500 $\mu$ M phenobarbital (PB), and in the absence or presence of 10 or 20 $\mu$ M ketoconazole (KT).

A-C. Total RNA was extracted and CYP3A4, 2B6 and 2C9 mRNA levels were analyzed by quantitative real-time PCR. The  $\beta$ -actin mRNA level was used to normalize data. Mean CYP mRNA levels from three cultures (FT212, 245 and 246) are expressed relative to the level observed in untreated cells.

D. In parallel experiments, hepatocytes (FT199) were cultured for 24 hours in the absence (DMSO) or presence of 10nM 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) and in the absence or presence of 10 or 20 $\mu$ M ketoconazole (KT). Total RNA was extracted and the CYP1A1 mRNA level was analyzed by Northern-Blot, the GAPDH mRNA level being used as a control.

**Figure 9. Ketoconazole reduces the inducible expression of CYP3A4 and CYP2B6 mRNA in cultured human hepatocytes treated with CITCO**

Primary human hepatocytes were cultured for 24 hours in the absence (DMSO) or presence of 100 nM CITCO, and in the absence or presence of 10 or 20 $\mu$ M ketoconazole (KT).

Total RNA was extracted and CYP3A4 (A) and CYP2B6 (B) mRNA levels were analyzed by real-time quantitative RT-PCR. The  $\beta$ -actin mRNA level was used to normalize data. Mean CYP mRNA levels from cultures FT261 are expressed relative to the level observed in untreated cells.

**Figure 10. Ketoconazole reduces the inducible expression of phase II and phase III system mRNA in cultured human hepatocytes treated with rifampicin and phenobarbital**

Primary human hepatocytes were cultured for 24 hours in the absence or presence of 20 $\mu$ M rifampicin (RIF) or 500 $\mu$ M phenobarbital (PB), and in the absence or presence of 10 or 20 $\mu$ M ketoconazole (KT).

Total RNA was extracted and GSTA1 (A), GSTA2 (B), UGT1A1 (C), SLC21A6 (D), and MRP2 (E) mRNA levels were analyzed by real-time quantitative RT-PCR. The  $\beta$ -actin mRNA level was used to normalize data. Mean mRNA levels from two cultures (FT245 and 246) are expressed relative to the level observed in uninduced cells (UT). Statistical analysis, Student t test: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

**Figure 11. Effect of azole derivatives on GRE-luc transactivation in HeLa cells**

HeLa-MMTV-luc cells were cultured for 4 hours in the absence or presence of 100 nM dexamethasone and increasing concentrations (10 to 20 or 10 to 40  $\mu$ M) of ketoconazole (used as control), miconazole and fluconazole (KT, M, F). Cell lysates were prepared and analyzed for LUC activity and protein content. Data are normalized with respect to those obtained in the presence of dexamethasone and in the absence of azole compound (-). Error bars represent the standard deviations of 5 independent experiments. Statistical analysis, Student t test: \*  $p < 0.05$ .

**Figure 12. Effect of azole derivatives on dexamethasone binding to hGR *in vitro***

Cytosolic extracts were prepared from pSG-5-hGR transiently transfected COS-1 cells, and incubated with 3nM [ $^3$ H]-dexamethasone alone (100% binding) or in combination with

increasing concentrations (1-100 $\mu$ M) of ketoconazole, miconazole and fluconazole (KT, M, F). See legend Figure 3 for further details and controls. Statistical analysis, Student t test: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

**Figure 13. Effect of azole derivatives on TAT, PXR and CAR mRNA levels in cultured human hepatocytes**

Primary human hepatocytes were cultured for 24 hours in the absence or presence of 10 or 20 $\mu$ M of ketoconazole (used as control), miconazole and fluconazole (K, M, F). Total RNA was extracted and analyzed by real-time quantitative RT-PCR for TAT, CAR and PXR mRNA. The  $\beta$ -actin mRNA was used to normalize data. Mean mRNA levels from two cultures (FT257 and 259) are expressed relative to the level observed in untreated cells (UT).

**Figure 14. Effect of fluconazole on the inducible expression of CYP3A4 and CYP2B6 mRNA in cultured human hepatocytes treated with rifampicin and phenobarbital**

Primary human hepatocytes were cultured for 24 hours in the absence or presence of 20 $\mu$ M rifampicin (RIF) or 500 $\mu$ M phenobarbital (PB), and in the absence or presence of 10 or 20 $\mu$ M fluconazole (F). Total RNA was extracted and CYP3A4 (A) and CYP2B6 (B) mRNA levels were analyzed by real-time quantitative RT-PCR. The  $\beta$ -actin mRNA level was used to normalize data. Mean CYP mRNA levels from cultures FT261 are expressed relative to the level observed in untreated cells.






Figure 1

**A**



**B**



**Figure 2**




Figure 3





Figure 4



**Figure 5**






Figure 6





Figure 7








Figure 8



**Figure 9**




Figure 10




Figure 11




Figure 12




Figure 13






Figure 14